Defining Globalization

Introduction

Йlan was initially incorporated in Ireland in 1969 as a Private Limited Company They later floated their shares on the Stock Exchange and became a Public Limited Company on 3rd June 1984. The company suffered a number of setbacks in 2002 which saw their share price collapse from $65 to $1.05 in the space of six months. These setbacks initiated a recovery plan which was formally completed in February of 2004 the purpose of which was to restructure their businesses, their assets and their Balance Sheets.

Their marketable products include medication (Tysabri, which recently has been voluntarily withdrawn from the market) for the treatment of Multiple sclerosis, Crohn's Disease and Rheumatoid Arthritis; they also market a synthetic intrathecal medication (Prialt) for the relief of severe chronic pain where the patient has become unresponsive to previous therapies.

Their marketable products also include Maxipime and Azactam for the treatment of severe bacterial infections which are such a nature that they must be treated in Hospital settings. Йlan are heavily committed to their research and development programmes in relation to Alzheimer's disease and Parkinson's disease. . They are focused on the discovery, the development, and the marketing of products and services in neurology, pain management, and autoimmune diseases and in the development and commercialisation of products using its extensive range of proprietary drug-delivery technologies.

Working Capital

Йlan's Working Capital can be defined as its Current Assets minus its Current Liabilities. All companies need adequate liquid resources to promote healthy day to day cash flow. Йlan must maintain sufficient liquidity in order to ensure its survival in the long term. Even a profitable company may fail, if it does not maintain adequate cash flow